The GLP-1 review-consensus map: every major ranking's pick, its incentives, and where the numbers actually agree

Search "best tirzepatide" and the results page is a hall of mirrors: sponsored slots dressed as editorial, providers ranking themselves, affiliates ranking their payers, and a few honest signals buried in Reddit threads. This page maps the whole landscape — including our own position in it — because the fastest way to trust any ranking is to see who benefits from it.

What each major ranking says, with its incentive attached

Forbes Health (Aug 4, 2026) names Hims & Hers its affordable-tirzepatide pick for "versatility" and Remedy Meds for "customer support," each at 4.3 stars in its system — and simultaneously buys the sponsored slots above its own organic listing, an affiliate-plus-ads model where star math is proprietary. WebMD's tirzepatide "rankings" in search results are explicitly sponsored placements ("sponsored.webmd.com"), which is disclosure by URL if you know to look. GLP-1 Watchdog crowns Embody at 9.4/10 and $69/month — a score without published arithmetic, wrapped in countdown timers and "was $299" strikethroughs, which is why we log the $69 as an unverified intro rather than a price. PlexusDx ranks its own $289 program first in its own comparison article — the purest conflict in the set, and a useful calibration point for every other self-scored list. policylab.us puts BMI Doctors second at a reported $139/month on twelve months, the claim that added BMI Doctors to our universe today. tirzepatidereview.com ranks NexLife first as "cheapest verified all-inclusive" — and here the mirror faces us: NexLife is our disclosed commercial partner too, we cannot verify that site's independence or methodology, and a ranking that agrees with our partner's interests deserves more scrutiny from us, not less. So we log it as an unverified external signal, nothing more. Noom and Maven Clinic publish brand-favoring comparisons that steer to LillyDirect — content marketing with a clear house position, though Noom's core price fact (vials from $299) checks out against Lilly's own announcement.

What patients themselves aggregate to

Strip out everyone with a funnel and the drug-level signal is unusually strong: on Drugs.com, tirzepatide holds an 8.5/10 average across 3,381 patient reviews with 78% positive; on WebMD, Mounjaro averages 4.1/5 across 661 reviews with about 83% reporting positive effect — consumer-review numbers most prescription drugs never approach, and consistent with the trial record (20.9% at 15 mg in SURMOUNT-1; superiority over semaglutide in SURMOUNT-5; a supportive 2025 Cochrane review). Provider-level patient signal is thinner and noisier, but the most useful single thread we've logged is r/compoundedtirzepatide's recurring criteria — fair price, consistency over time, no potency swings — plus a July 2026 report of Embody holding a flat $129 tirzepatide rate in practice. Community reports are anecdotes, not audits; we log them with dates and treat them as leads for verification, which is exactly what the Embody fact sheet shows.

Why the rankings disagree — four mechanical reasons

The divergence isn't mysterious once you name the mechanisms. Fee accounting: some lists rank advertised medication price, others all-in cost — Mochi is "cheap" in the first frame and ~$278 in the second, and no list that hides its accounting can be compared to one that doesn't. Intro anchoring: a $69 first month with unverified renewal beats a $139 flat rate in any list that ranks month one, and loses to it in any list that ranks month twelve. Sponsorship gravity: when payment and placement correlate, "best" drifts toward "best-paying" unless a methodology actively resists it. Self-interest: providers reviewing markets they sell into rank themselves first with metronomic reliability. Our answer to all four is structural rather than rhetorical: a public dataset where every figure carries a status and a source, category calls computed from it, a partner (NexLife) whose figures wear the operator label until our checkout walk verifies them, and a correction log that today includes us fixing our own stale LillyDirect number — because the test of a methodology isn't whether it flatters us, it's whether it catches us.

Where the field actually converges

For all the noise, four consensus facts survive every list worth reading. Tirzepatide is the efficacy leader — every ranking, aggregate, and trial agrees. The legitimate compounded floor sits in the $99–199 band, with everything below it demanding intro-price skepticism and everything above ~$300 competing directly against brand vials at $299–449. Insurance, where possible, beats every cash number — the point Ro's model is built on and the Medicare Bridge institutionalized. And the deciding variables are the boring ones no score captures: the named pharmacy, the maintenance-dose price, and the cancellation terms. Which is to say: the consensus, properly read, is an argument for exactly the fields our dataset tracks — and against every 9.4/10 that can't show its arithmetic.